EW

EW

USD

Edwards Lifesciences Corporation Common Stock

$84.150+1.100 (1.325%)

Real-time Price

Healthcare
Medical devices
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$83.050

High

$84.830

Low

$82.890

Volume

2.64M

Company Fundamentals

Market Cap

49.4B

Industry

Medical devices

Country

United States

Trading Stats

Avg Volume

4.58M

Exchange

NYQ

Currency

USD

52-Week Range

Low $64.89Current $84.150High $87.09

Related News

Analyst Upgrades

Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences with a Hold and raises the price target from $87 to $90.

View more
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90
Analyst Upgrades

Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99

Barclays analyst Matt Miksic maintains Edwards Lifesciences with a Overweight and raises the price target from $95 to $99.

View more
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99
Analyst Upgrades

Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $96

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences with a Buy and raises the price target from $95 to $96.

View more
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $96
Analyst Upgrades

JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $90

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences with a Neutral and raises the price target from $85 to $90.

View more
JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $90
Analyst Upgrades

Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $104

Goldman Sachs analyst David Roman maintains Edwards Lifesciences with a Buy and raises the price target from $94 to $104.

View more
Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $104
Analyst Upgrades

Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $95

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences with a Overweight and raises the price target from $90 to $95.

Analyst Upgrades

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $95

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences with a Outperform and raises the price target from $89 to $95.